{
  "emaEpar": [
    {
      "activeSubstance": "Temsirolimus",
      "conditionIndication": "Renal-cell carcinomaTorisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors.Mantle-cell lymphomaTorisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL).",
      "inn": "temsirolimus",
      "marketingAuthorisationDate": "2007-11-19 01:00:00",
      "marketingAuthorisationHolder": "Pfizer Europe MA EEIG",
      "medicineName": "Torisel",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/torisel"
    }
  ],
  "fdaDrugLabel": [],
  "id": "Temsirolimus",
  "nciThesaurus": {
    "casRegistry": "162635-04-3",
    "chebiId": "",
    "chemicalFormula": "C56H87NO16",
    "definition": "An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.",
    "fdaUniiCode": "624KN6GM2T",
    "identifier": "C1844",
    "preferredName": "Temsirolimus",
    "semanticType": "Organic Chemical",
    "subclassOf": [],
    "synonyms": [
      "42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin",
      "CCI-779",
      "CCI-779 Rapamycin Analog",
      "Cell Cycle Inhibitor 779",
      "Rapamycin Analog",
      "Rapamycin Analog CCI-779",
      "TEMSIROLIMUS",
      "Temsirolimus",
      "Torisel",
      "temsirolimus"
    ]
  }
}